Stem Cell Challenges in the Treatment of Neurodegenerative Disease

CNS Neuroscience and Therapeutics

Volumn 18, Issue 2, 2012, Pages 142-148

  Feng, Zhongling ^a   Gao, Feng ^b  

^a Biomedical Group   (United States)

^b Wintherix LLC   (United States)

Author keywords

Alzheimer's disease; Amyotrophic lateral sclerosis; Multiple sclerosis; Parkinson's disease; Stem cell

Indexed keywords

AMYLOID PRECURSOR PROTEIN; BRAIN DERIVED NEUROTROPHIC FACTOR; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; ENZYME INHIBITOR; LEVODOPA;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; AUTOLOGOUS STEM CELL TRANSPLANTATION; BRAIN DEPTH STIMULATION; DEGENERATIVE DISEASE; DYSKINESIA; EMBRYONIC STEM CELL; HUMAN; MOTOR DYSFUNCTION; MULTIPLE SCLEROSIS; NEURAL STEM CELL; NONHUMAN; PARKINSON DISEASE; PLURIPOTENT STEM CELL; REVIEW; STEM CELL TRANSPLANTATION;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; CLINICAL TRIALS AS TOPIC; HUMANS; NEURODEGENERATIVE DISEASES; PARKINSON DISEASE; STEM CELL TRANSPLANTATION; STEM CELLS; TREATMENT OUTCOME;

EID: 84856790496     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/j.1755-5949.2011.00239.x     Document Type: Review

References (58)

1. Brown RC, Lockwood AH, Sonawane BR. Neurodegenerative diseases: An overview of environmental risk factors. Environ Health Perspect 2005;113:1250-1256.
2. Gage FH. Neurogenesis in the adult brain. J Neurosci 2002;22:612-613.
3. Hess DC, Borlongan CV. Stem cells and neurological diseases. Cell Prolif 2008;41(Suppl1):94-114.
4. Orlacchio A, Bernardi G, Orlacchio A, Martino S. Stem cells: An overview of the current status of therapies for central and peripheral nervous system diseases. Curr Med Chem 2010;17:595-608.
5. Lindvall O, Kokaia Z. Stem cells in human neurodegenerative disorders-time for clinical translation?. J Clin Invest 2010;120:29-40.
6. Kiskinis E, Eggan K. Progress toward the clinical application of patient-specific pluripotent stem cells. J Clin Invest 2010;120:51-59.
7. Shihabuddin LS, Aubert I. Stem cell transplantation for neurometabolic and neurodegenerative diseases. Neuropharmacology 2010;58:845-854.
8. Wijeyekoon R, Barker RA. Cell replacement therapy for Parkinson's disease. Biochim Biophys Acta 2009;1792:688-702.
9. Toriumi H, Yoshikawa M, Matsuda R, et al. Treatment of Parkinson's disease model mice with allogeneic embryonic stem cells: necessity of immunosuppressive treatment for sustained improvement. Neurol Res 2009;31:220-227.
10. Lindvall O, Kokaia Z. Prospects of stem cell therapy for replacing dopamine neurons in Parkinson's disease. Trends Pharmacol Sci 2009;30:260-267.
11. Jiang Y, Jahagirdar BN, Reinhardt RL, et al. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 2002;418: 41-49.
12. Bianco P, Riminucci M, Gronthos S, Robey PG. Bone marrowstromal stem cells: Nature, biology, and potential applications, Stem Cells 2001;19:180-192.
13. Rodolfa KT, Eggan K. A transcriptional logic for nuclear reprogramming. Cell 2006;126:652-655.
14. Tada M, Takahama Y, Abe K, Nakatsuji N, Tada T. Nuclear reprogramming of somatic cells by in vitro hybridizationwith ES cells. Curr Biol 2001;11:1553-1558.
15. Wernig M, Zhao JP, Pruszak J, et al. Neurons derived from reprogrammed fibroblasts functionally integrate into the fetal brain and improve symptoms of rats with Parkinson's disease. Proc Natl Acad Sci U S A 2008;105:5856-5861.
16. Cowan CA, Atienza J, Melton DA, Eggan K. Nuclear reprogramming of somatic cells after fusion with human embryonic stem cells. Science 2005;309:1369-1373.
17. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007;131:861-872.
18. Barzilay R, Ben-Zur T, Bulvik S, Melamed E, Offen D. Lentiviral delivery of LMX1a enhances dopaminergic phenotype in differentiated human bone marrow mesenchymal stem cells. Stem Cells Dev 2009;18:591-601.
19. Greene P. Cell-based therapies in Parkinson's disease. Curr Neurol Neurosci Rep 2009;9:292-297.
20. Soldner F, Hockemeyer D, Beard C, et al. Parkinson's disease patient-derived induced pluripotent stem cells free of viral reprogramming factors. Cell 2009;136:964-977.
21. Stroh A, Boltze J, Sieland K, et al. Impact of magnetic labeling on human and mouse stem cells and their long-term magnetic resonance tracking in a rat model of Parkinson disease. Mol Imaging 2009;8:166-178.
22. Isacson O, Bjorklund LM, Schumacher JM. Towards full restoration of synaptic and terminal function of the dopaminergic system in Parkinson's disease from regeneration and neuronal replacement by stem cells. Ann Neurol 2003;53:135-148.
23. Mendez I, Sanchez-Pernaute R, Cooper O, et al. Cell type analysis of functional fetal dopamine cell suspension transplants in the striatum and substantia nigra of patients with Parkinson's disease. Brain 2005;128:1498-1510.
24. Madhavan L, Daley BF, Paumier KL, Collier TJ. Transplantation of subventricular zone neural precursors induces an endogenous precursor cell response in a rat model of Parkinson's disease. J Comp Neurol 2009;515:102-115.
25. Isacson O, Kordower JH. Future of Cell and Gene Therapies for Parkinson's Disease. Ann Neurol 2008;64(suppl):S122-S138.
26. Bradley LJ, Taanman JW, Kallis C, Orrell RW. Increased sensitivity of myoblasts to oxidative stress in amyotrophic lateral sclerosis peripheral tissues. Exp Neurol 2009;218:92-97.
27. Appel SH, Engelhardt JI, Henkel JS, et al. Hematopoietic stem cell transplantation in patients with sporadic amyotrophic lateral sclerosis. Neurology 2008;71:1326-1334.
28. Hedlund E, Isacson O. ALS model glia can mediate toxicity to motor neurons derived from human embryonic stem cells. Cell Stem Cell 2008;3:575-576.
29. Di Giorgio FP, Boulting GL, Bobrowicz S, Eggan KC. Human embryonic stem cell-derived motor neurons are sensitive to the toxic effect of glial cells carrying an ALS-causing mutation. Cell Stem Cell 2008;3:637-648.
30. Dimos JT, Rodolfa KT, Niakan KK, et al. Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science 2008;321:1218-1221.
31. Ebert AD, Yu J, Rose FF Jr, et al. Induced pluripotent stem cells from a spinal muscular atrophy patient. Nature 2009;457:277-280.
32. Kaspar BK. Mesenchymal stem cells as trojan horses for GDNF delivery in ALS. Mol Ther 2008;16:1905-1906.
33. Suzuki M, McHugh J, Tork C, et al. Direct muscle delivery of GDNF with human mesenchymal stem cells improves motor neuron survival and function in a rat model of familial ALS. Mol Ther 2008;16:2002-2010.
34. Martinez HR, Gonzalez-Garza MT, Moreno-Cuevas JE, Caro E, Gutierrez-Jimenez E, Segura JJ. Stem-cell transplantation into the frontal motor cortex in amyotrophic lateral sclerosis patients. Cytotherapy 2009;11:26-34.
35. Deda H, Inci MC, Kürekçi AE, et al. Treatment of amyotrophic lateral sclerosis patients by autologous bone marrow-derived hematopoietic stem cell transplantation: A 1-year follow-up. Cytotherapy 2009;11:18-25.
36. Lunn JS, Hefferan MP, Marsala M, Feldman EL. Stem cells: Comprehensive treatments for amyotrophic lateral sclerosis in conjunction with growth factor delivery. Growth Factors 2009;27:133-140.
37. Zhongling Feng, Gang Zhao, Lei Yu. Neural stem cells and Alzheimer's disease: Challenges and hope. Am J Alzheimers Dis Other Demen 2009;24:52-57.
38. Sugaya K, Merchant S. How to Approach Alzheimer's Disease Therapy Using Stem Cell Technologies. Journal of Alzheimer's Disease 2008;15:241-254.
39. Lindvall O, Kokaia Z. Stem cells in human neurodegenerative disorders-time for clinical translation? J Clin Invest 2010;120:29-40.
40. Taupin P. Adult neurogenesis, neural stem cells and Alzheimer's disease: Developments, limitations, problems and promises. Curr Alzheimer Res 2009;6:461-470.
41. Blurton-Jones M, Kitazawa M, Martinez-Coria H, et al. Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease. Proc Natl Acad Sci U S A 2009;106:13594-13599.
42. Porayette P, Gallego MJ, Kaltcheva MM, Bowen RL, Vadakkadath Meethal S, Atwood CS. Differential processing of amyloid-beta precursor protein directs human embryonic stem cell proliferation and differentiation into neuronal precursor cells. J Biol Chem 2009;284:23806-23817.
43. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med 2000;343:938-952.
44. Einstein O, Friedman-Levi Y, Grigoriadis N, Ben-Hur T. Transplanted neural precursors enhance host brain-derived myelin regeneration. J Neurosci 2009;29:15694-15702.
45. Barhum Y, Gai-Castro S, Bahat-Stromza M, Barzilay R, Melamed E, Offen D. Intracerebroventricular transplantation of human mesenchymal stem cells induced to secrete neurotrophic factors attenuates clinical symptoms in a mouse model of multiple sclerosis. J Mol Neurosci 2010;41:129-137.
46. Makar TK, Bever CT, Singh IS, et al. Brain-derived neurotrophic factor gene delivery in an animal model of multiple sclerosis using bone marrow stem cells as a vehicle. J Neuroimmunol 2009;210:40-51.
47. Olanow CW, Goetz CG, Kordower JH, et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol 2003;54:403-414.
48. Freed CR, Greene PE, Breeze RE, et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 2001;344:710-719.
49. Boucherie C, Hermans E. Adult stem cell therapies for neurological disorders: Benefits beyond neuronal replacement? J Neurosci Res 2009;87:1509-1521.
50. Knoepfler PS. Deconstructing stem cell tumorigenicity: A roadmap to safe regenerative medicine. Stem Cells 2009;27:1050-1056.
51. Alison MR, Murphy G, Leedham S. Stem cells and cancer: A deadly mix. Cell Tissue Res 2008;331:109-124.
52. Ming GL, Song H. Adult neurogenesis in the mammalian central nervous system. Annu Rev Neurosci 2005;28:223-250.
53. Feng LR, Maguire-Zeiss KA. Gene therapy in Parkinson's disease: Rationale and current status. CNS Drugs 2010;24:177-192.
54. McMenamin MM, Wood MJ. Progress and prospects: Immunobiology of gene therapy for neurodegenerative disease: Prospects and risks. Gene Ther 2010;17:448-458.
55. Manfredsson FP, Okun MS, Mandel RJ. Gene therapy for neurological disorders: Challenges and future prospects for the use of growth factors for the treatment of Parkinson's disease. Curr Gene Ther 2009;9:375-388.
56. Nathalie Cartier, Salima Hacein-Bey-Abina, Cynthia C. Hematopoietic Stem Cell Gene Therapy with a Lentiviral Vector in X-Linked Adrenoleukodystrophy. Science 2009;326:818-823.
57. David A. Williams and Christopher Baum. Gene Therapy-New Challenges Ahead. Science 2003;302:400-401.
58. Vierbuchen T, Ostermeier A, Pang ZP, Kokubu Y, Südhof TC, Wernig M. Direct conversion of fibroblasts to functional neurons by defined factors. Nature 2010;463:1035-1041.